TrialThe oncologist2023

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.

Pedro C Barata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.